These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 17049513)

  • 21. Osteoclast culture and resorption assays.
    Bradley EW; Oursler MJ
    Methods Mol Biol; 2008; 455():19-35. PubMed ID: 18463808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Staphylococcus aureus capsular material promotes osteoclast formation.
    Lau YS; Wang W; Sabokbar A; Simpson H; Nair S; Henderson B; Berendt A; Athanasou NA
    Injury; 2006 May; 37 Suppl 2():S41-8. PubMed ID: 16651071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells.
    Jimi E; Nakamura I; Duong LT; Ikebe T; Takahashi N; Rodan GA; Suda T
    Exp Cell Res; 1999 Feb; 247(1):84-93. PubMed ID: 10047450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impaired osteoclastogenesis by staphylococcal lipoteichoic acid through Toll-like receptor 2 with partial involvement of MyD88.
    Yang J; Ryu YH; Yun CH; Han SH
    J Leukoc Biol; 2009 Oct; 86(4):823-31. PubMed ID: 19602669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.
    Lavallard VJ; Pradelli LA; Paul A; Bénéteau M; Jacquel A; Auberger P; Ricci JE
    Cancer Res; 2009 Apr; 69(7):3013-20. PubMed ID: 19318579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitory effect of (-)-saucerneol on osteoclast differentiation and bone pit formation.
    Kim SN; Kim MH; Kim YS; Ryu SY; Min YK; Kim SH
    Phytother Res; 2009 Feb; 23(2):185-91. PubMed ID: 18690659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Receptor activator of nuclear factor-kappa B ligand induces osteoclast formation in RAW 264.7 macrophage cells via augmented production of macrophage-colony-stimulating factor.
    Islam S; Hassan F; Tumurkhuu G; Dagvadorj J; Koide N; Naiki Y; Yoshida T; Yokochi T
    Microbiol Immunol; 2008 Dec; 52(12):585-90. PubMed ID: 19120972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
    Hussein O; Tiedemann K; Komarova SV
    Bone; 2011 Feb; 48(2):202-11. PubMed ID: 20849994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M; Nguyen TK; Dent P; Grant S
    Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology.
    Ross FP; Teitelbaum SL
    Immunol Rev; 2005 Dec; 208():88-105. PubMed ID: 16313343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Naringenin inhibits human osteoclastogenesis and osteoclastic bone resorption.
    La VD; Tanabe S; Grenier D
    J Periodontal Res; 2009 Apr; 44(2):193-8. PubMed ID: 18705650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cystatin B as an intracellular modulator of bone resorption.
    Laitala-Leinonen T; Rinne R; Saukko P; Väänänen HK; Rinne A
    Matrix Biol; 2006 Apr; 25(3):149-57. PubMed ID: 16321512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Receptor tyrosine kinase inhibition causes simultaneous bone loss and excess bone formation within growing bone in rats.
    Nurmio M; Joki H; Kallio J; Määttä JA; Väänänen HK; Toppari J; Jahnukainen K; Laitala-Leinonen T
    Toxicol Appl Pharmacol; 2011 Aug; 254(3):267-79. PubMed ID: 21586300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
    Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
    Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways.
    Hu JP; Nishishita K; Sakai E; Yoshida H; Kato Y; Tsukuba T; Okamoto K
    Eur J Pharmacol; 2008 Feb; 580(1-2):70-9. PubMed ID: 18083161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteasome inhibitors induce osteoclast survival by activating the Akt pathway.
    Kwak HB; Lee MS; Kim HS; Cho HJ; Kim JW; Lee ZH; Oh J
    Biochem Biophys Res Commun; 2008 Dec; 377(1):1-6. PubMed ID: 18492488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone morphogenetic protein-9 activates Smad and ERK pathways and supports human osteoclast function and survival in vitro.
    Fong D; Bisson M; Laberge G; McManus S; Grenier G; Faucheux N; Roux S
    Cell Signal; 2013 Apr; 25(4):717-28. PubMed ID: 23313128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imatinib mesylate does not increase bone volume in vivo.
    O'Sullivan S; Naot D; Callon KE; Watson M; Gamble GD; Ladefoged M; Karsdal MA; Browett P; Cornish J; Grey A
    Calcif Tissue Int; 2011 Jan; 88(1):16-22. PubMed ID: 20978751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors.
    Dewar AL; Domaschenz RM; Doherty KV; Hughes TP; Lyons AB
    Leukemia; 2003 Sep; 17(9):1713-21. PubMed ID: 12970769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.